GSK plc's Schedule 13D Filing for CureVac N.V.

GSK plc, a global biopharma company, filed a Schedule 13D with the SEC regarding its ownership of common shares in CureVac N.V., a Netherlands-based biopharmaceutical company. The filing discloses that GSK, through its wholly-owned subsidiary Glaxo Group Limited (GGL), owns 16,591,937 common shares, representing approximately 74% of the outstanding shares. The shares were acquired for investment purposes, with GGL using internal resources for the purchases. GSK also entered into a Tender and Support Agreement with BioNTech SE, agreeing to tender all its shares in an exchange offer and vote in favor of certain proposals related to the offer. The filing includes details on the sources of funds, the purpose of the transactions, and the agreements involved. The importance of this filing is HIGH due to the significant ownership stake and the strategic agreements disclosed.